308 related articles for article (PubMed ID: 26420061)
21. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
22. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
24. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
25. [New treatment strategy of multiple myeloma for cure].
Murakami H; Handa H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
27. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
[TBL] [Abstract][Full Text] [Related]
28. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
29. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
30. [A case-control study of multiple myeloma patients with central nervous system involvement].
Li L; Feng ZY; Guo P; He HY; Lu J; Liu J; Qiang WT; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1016-1020. PubMed ID: 36709107
[No Abstract] [Full Text] [Related]
31. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
32. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
34. Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Barlogie B; Tricot G; Anaissie E; Shaughnessy J; Rasmussen E; van Rhee F; Fassas A; Zangari M; Hollmig K; Pineda-Roman M; Lee C; Talamo G; Thertulien R; Kiwan E; Krishna S; Fox M; Crowley J
N Engl J Med; 2006 Mar; 354(10):1021-30. PubMed ID: 16525139
[TBL] [Abstract][Full Text] [Related]
35. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
[TBL] [Abstract][Full Text] [Related]
36. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Krejci M; Scudla V; Tothova E; Schutzova M; Koza V; Adam Z; Krivanova A; Pour L; Buchler T; Sandecka V; Kralova D; Zahradova L; Vorlicek J; Mayer J; Hajek R
Clin Lymphoma Myeloma; 2009 Dec; 9(6):436-42. PubMed ID: 19951883
[TBL] [Abstract][Full Text] [Related]
38. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
